Long-term efficacy and safety of vimseltinib in patients with tenosynovial giant cell tumor: 2-year results from the MOTION phase 3 trial
Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
Safety, efficacy, and patient-reported outcomes with vimseltinib in patients with tenosynovial giant cell tumor who received prior anti–colony-stimulating factor 1 therapy: ongoing phase 2 study
Safety and efficacy with vimseltinib in patients with tenosynovial giant cell tumor who received no prior anti–colony-stimulating factor 1 therapy: ongoing phase 2 study
Safety and efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT): Long-term phase 1 update.
Presentation of New Clinical Study Results from DCC-3116 and Vimseltinib at the European Society for Medical Oncology (ESMO) Congress 2022.
Efficacy and safety of vimseltinib in tenosynovial giant cell tumor (TGCT): Phase 2 expansion.
Initial monotherapy results of a phase 1 first‑in‑human study of ULK1/2 inhibitor DCC‑3116 alone and in combination with MAPK pathway inhibition.
Presentation of New Clinical Study Results from Rebastinib and Vimseltinib at the European Society for Medical Oncology (ESMO) Congress 2021.
Phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.
